-

MEDISCA Promotes Efficiency and Quality Control with New Patent for Planetary Mixers

MONTREAL--(BUSINESS WIRE)--MEDISCA Pharmaceutique Inc. (“MEDISCA”), a global leader of innovative products and services for the pharmaceutical compounding industry, is pleased to announce the issuance of United States Patent 10,420,705, covering an adapter for use in planetary mixers. This adapter is useful for those seeking the benefits of high homogeneity and short mixing time afforded by a rotation-revolution mixer, while keeping the final mixed product in the same dispenser that pharmacists, for example, will use in their regular compounding activities.

MEDISCA’s innovative and ongoing contributions in the field of pharmaceutical compounding is reflected in this additional issued patent in its global patent portfolio. Some of these proprietary improvements and innovations, including U.S. Patents 10,420,705 and 10,231,903, cover uses and functionalities of the MAZ™, the successful brand of a high-performance planetary mixer used in an increasing number of compounding pharmacies worldwide and is available exclusively through MEDISCA.

"If we discover that our clients are struggling with a specific process, we go to work finding innovative solutions to fit their needs”, said Panagiota Danopoulos, Senior Director at MEDISCA. "We are dedicated to not only providing the highest quality ingredients for medications, but ensuring that each step of the compounding process is safe and effective for those we serve."

MEDISCA continues to grow its intellectual property portfolios in Canada, U.S.A and globally in its key commercial markets. MEDISCA will continue its vigilance in the pharmaceutical compounding industry in order to protect its numerous innovative products and services, as well as the significant investments the company makes in research and development, marketing and its patent and trademark portfolios globally.

Contacts

Alphée Beauchamp
6090 Henri-Bourassa Blvd W, Saint-Laurent, Quebec H4R 3A6, Canada abeauchamp@medisca.com
(514) 333-7811 x1230

More News From MEDISCA Pharmaceutique Inc.

Medisca and EUROAPI Form Strategic Partnership to Strengthen API Access for Pharmaceutical Compounding

MONTREAL--(BUSINESS WIRE)--Medisca and EUROAPI have formed a strategic partnership focused on expanding API access for pharmaceutical compounding, creating differentiated access in North America and establishing a broader framework for international growth and peptide collaboration. For more than three decades, Medisca has built its business around the evolving needs of pharmaceutical compounders. That starts with the products it chooses to bring to market but extends much further to the manufa...

Medisca Launches Global Peptide Division

MONTREAL--(BUSINESS WIRE)--Medisca today announced the launch of Medisca Peptides, a dedicated global division focused on expanding access to API-grade peptides and building an integrated peptide platform for pharmaceutical and personalized medicine markets worldwide. As the peptide landscape evolves, Medisca is proactively building the capabilities and infrastructure needed to support API-grade peptides within applicable regulatory frameworks. The launch represents a significant long-term comm...

Medisca Enters Its Next Chapter Under Founder Antonio Dos Santos

MONTREAL--(BUSINESS WIRE)--For more than 35 years, Dos Santos has helped shape Medisca into a global leader in pharmaceutical compounding. As Chief Executive Officer, he will lead the company's long-term strategy, with a focus on expanding Medisca's global reach, investing in new areas of growth, strengthening strategic partnerships, and continuing to advance the products, services, education, and expertise that healthcare professionals rely on every day. "When I founded Medisca, my vision was...
Back to Newsroom